Liafensine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Liafensine
Liafensine.svg
Systematic (IUPAC) name
6-[(4S)-2-Methyl-4-(2-naphthyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-3-pyridazinamine
Clinical data
Legal status
  • Development terminated
Routes Oral
Identifiers
CAS number 1198790-53-2
ATC code None
PubChem CID 58212050
ChemSpider 29271896
Chemical data
Formula C24H22N4 
Molecular mass 366.458 g/mol

Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder.[1] Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was terminated in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision which was made likely based on its increased capacity for side effects as well as its potential for abuse.[1]

See also[edit]

References[edit]

  1. ^ a b "Digest". Progress in Neurology and Psychiatry 17 (5): 41–43. 2013. doi:10.1002/pnp.305. ISSN 1367-7543.